Systematic Evaluation and Meta-Analysis of the Efficacy and Safety of Shenfu Injection in the Treatment of Septic Cardiomyopathy

Objective: To evaluate the efficacy and safety of Shenfu injection in the treatment of septic cardiomyopathy. Methods: Literatures on Shenfu injection for the treatment of sepsis published from the establishment of each database to December 31, 2020, were searched by computer; Cochrane risk-of-bias tool was used for evaluating the quality of literatures, and Review Manager 5.4 software was used for meta-analysis. Results: Twenty random controlled trials (RCTs) were included, with a total of 1,179 patients; the meta-analysis showed that the routine treatment of Western medicine combined with Shenfu injection can reduce the 28-day mortality, the length of hospital stay, cardiac troponin I (cTnI), and N-terminal pro-brain natriuretic peptide (NT-proBNP) as well as improve the left ventricular ejection fraction (LVEF) with low incidence of adverse reactions. Conclusion: Western medicine combined with Shenfu injection can further reduce myocardial injury in patients with sepsis and improve cardiac function as well as the prognosis of patients with septic cardiomyopathy.